Intra Financial Statements From 2010 to 2025
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
Check Intra Cellular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intra Cellular's main balance sheet or income statement drivers, such as , as well as many indicators such as . Intra financial statements analysis is a perfect complement when working with Intra Cellular Valuation or Volatility modules.
Intra |
Intra Cellular Therapies Company Profit Margin Analysis
Intra Cellular's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Intra Cellular Profit Margin | (0.11) % |
Most of Intra Cellular's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra Cellular Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Intra Cellular Therapies has a Profit Margin of -0.1097%. This is 99.02% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 91.36% lower than that of the firm.
Intra Cellular Therapies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Intra Cellular's current stock value. Our valuation model uses many indicators to compare Intra Cellular value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intra Cellular competition to find correlations between indicators driving Intra Cellular's intrinsic value. More Info.Intra Cellular Therapies is rated third overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intra Cellular's earnings, one of the primary drivers of an investment's value.About Intra Cellular Financial Statements
Investors use fundamental indicators, such as Intra Cellular's revenue or net income, to determine how well the company is positioned to perform in the future. Although Intra Cellular's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |